☆ 4.3 Review

Clinical efficacy and safety of bispecific antibodies for the treatment of solid tumors: a systematic review and meta-analysis

EXPERT REVIEW OF ANTICANCER THERAPY (2023)

Related references

Note: Only part of the references are listed.

Article Pharmacology & Pharmacy

Tebentafusp: First Approval

Sohita Dhillon

Summary: Tebentafusp is a targeted therapy for uveal melanoma and malignant melanoma that binds to specific receptors and T cells, resulting in the direct lysis of tumor cells. It has received approval for the treatment of uveal melanoma in the USA and is under regulatory review in other countries.

DRUGS (2022)

Add to Collection

Review Multidisciplinary Sciences

Clinical safety and efficacy of bispecific antibody in the treatment of solid tumors: A protocol for a systematic review

Seyed Aria Nejadghaderi et al.

Summary: This systematic review and meta-analysis aims to evaluate the safety and efficacy of bispecific antibodies (BsAbs) in the treatment of solid tumors. The study will involve searching multiple databases, screening and reviewing eligible studies, and conducting data collection and quality assessment. The findings of this study will provide valuable information for physicians and researchers.

PLOS ONE (2022)

Add to Collection

Review Immunology

Review Article Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody

Dain Moon et al.

Summary: In the era of immunotherapeutic control of cancers, advances in biotechnology, especially in Ab engineering, have provided new candidates for therapeutic immunooncology. Among them, TCEBs that target both T cells and tumor cells through tumor cell specific antigens are the most promising BsAbs. The development of TCEBs and their diverse formats, characteristics, and functional mechanisms are discussed, including the challenges and drawbacks associated with current TCEB therapy.

IMMUNE NETWORK (2022)

Add to Collection

Review Hematology

Bispecific antibody therapy, its use and risks for infection: Bridging the knowledge gap

Anthony P. Longhitano et al.

Summary: BsAbs show promise in treating relapsed haematological malignancies, but also present risks of infections, including cytokine release syndrome and severe infections, highlighting the importance of infection prevention strategies.

BLOOD REVIEWS (2021)

Add to Collection

Article Immunology

Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings

Horst-Dieter Hummel et al.

Summary: The study reported the results of a first-in-human study of pasotuxizumab in patients with advanced castration-resistant prostate cancer. The data showed significant PSA response in some patients, suggesting the potential efficacy of this therapy in treating solid tumors.

IMMUNOTHERAPY (2021)

Add to Collection

Review Medicine, General & Internal

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

Matthew J. Page et al.

Summary: The PRISMA statement was designed to help systematic reviewers transparently report the purpose, methods, and findings of their reviews. The updated PRISMA 2020 statement includes new reporting guidance, a 27-item checklist, an abstract checklist, and revised flow diagrams for reviews.

BMJ-BRITISH MEDICAL JOURNAL (2021)

Add to Collection

Review Immunology

Bispecific Antibodies: From Research to Clinical Application

Jiabing Ma et al.

Summary: Bispecific antibodies (BsAbs) have two binding sites directed at different antigens or epitopes, and their clinical therapeutic effects are superior to monoclonal antibodies (MoAbs), used in tumor immunotherapy and other disease treatments. Over 30 mature commercial technology platforms have been utilized to generate and develop BsAbs based on heterologous recombination of heavy chains and light chains, with three BsAbs receiving market approval.

FRONTIERS IN IMMUNOLOGY (2021)

Add to Collection

Review Oncology

The promise of bispecific antibodies: Clinical applications and challenges

Sun Min Lim et al.

Summary: The use of monoclonal antibodies for cancer therapy has been successful in the past 30 years, and recent progress has been made with technologies involving bispecific and multi-specific antibodies. Bispecific antibodies can bind two distinct epitopes and have potential clinical applications, making them a valuable asset for cancer patients.

CANCER TREATMENT REVIEWS (2021)

Add to Collection

Article Pharmacology & Pharmacy

Amivantamab: First Approval

Yahiya Y. Syed

Summary: Amivantamab, a bispecific monoclonal antibody targeting EGFR and MET for NSCLC, has received approval in the USA and is undergoing preregistration in multiple countries worldwide.

DRUGS (2021)

Add to Collection

Review Pharmacology & Pharmacy

Advances in the treatment of platinum resistant epithelial ovarian cancer: an update on standard and experimental therapies

Shuk on Annie Leung et al.

Summary: PROC is defined as disease recurrence within 6 months of completing platinum-based chemotherapy, generally associated with poor outcomes and low response rates. Recent developments in therapeutics based on biomarkers and a more nuanced understanding of DNA repair and immunologic pathways have led to novel treatment options, such as PARP inhibitors, cell cycle checkpoint inhibitors, and immune checkpoint inhibitors.

EXPERT OPINION ON INVESTIGATIONAL DRUGS (2021)

Add to Collection

Review Immunology

Adverse events associated with immune checkpoint inhibitors in patients with breast cancer: A systematic review and meta-analysis

Maryam Balibegloo et al.

Summary: The results indicated that AEs and irAEs caused by ICIs were more common in patients with breast cancer.

INTERNATIONAL IMMUNOPHARMACOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma

Paul Nathan et al.

Summary: The randomized trial of tebentafusp for metastatic uveal melanoma showed a higher 1-year overall survival rate among patients who received tebentafusp compared to those who received the investigator's choice of therapy, indicating superior efficacy.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Oncology

The McCAVE Trial: Vanucizumab plus mFOLFOX-6 Versus Bevacizumab plus mFOLFOX-6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)

Johanna C. Bendell et al.

ONCOLOGIST (2020)

Add to Collection

Article Oncology

Randomized, double-blind, placebo-controlled phase II study of istiratumab (MM-141) plus nab-paclitaxel and gemcitabine versus nab-paclitaxel and gemcitabine in front-line metastatic pancreatic cancer (CARRIE)

M. Kundranda et al.

ANNALS OF ONCOLOGY (2020)

Add to Collection

Review Immunology

Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics

Heliang Li et al.

CELLULAR & MOLECULAR IMMUNOLOGY (2020)

Add to Collection

Review Oncology

Systemic Therapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma- A Systematic Review and Meta-Analysis

Ashley Lau et al.

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2020)

Add to Collection

Review Oncology

The tumour microenvironment in pancreatic cancer - clinical challenges and opportunities

Won Jin Ho et al.

NATURE REVIEWS CLINICAL ONCOLOGY (2020)

Add to Collection

Review Immunology

Development and clinical application of bispecific antibody in the treatment of colorectal cancer

Maryam Balibegloo et al.

EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2020)

Add to Collection

Article Biotechnology & Applied Microbiology

Efficiency of CAR-T Therapy for Treatment of Solid Tumor in Clinical Trials: A Meta-Analysis

Bin Hou et al.

DISEASE MARKERS (2019)

Add to Collection

Meeting Abstract Oncology

Phase 1 study of pasotuxizumab (BAY 2010112), a PSMA-targeting Bispecific T cell Engager (BiTE) immunotherapy for metastatic castration-resistant prostate cancer (mCRPC).

Horst-Dieter Hummel et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Review Oncology

Chimeric Antigen Receptor T-cell (CAR T) Therapy for Hematologic and Solid Malignancies: Efficacy and Safety-A Systematic Review with Meta-Analysis

Wen-Liang Yu et al.

CANCERS (2019)

Add to Collection

Review Oncology

Targeted and novel therapy in advanced gastric cancer

Julie H. Selim et al.

EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2019)

Add to Collection

Review Hematology

Efficacy and safety of bispecific T-cell engager (BiTE) antibody blinatumomab for the treatment of relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin's lymphoma: a systemic review and meta-analysis

Jian Yu et al.

HEMATOLOGY (2019)

Add to Collection

Review Hematology

Bispecific antibody based therapeutics: Strengths and challenges

Archana Thakur et al.

BLOOD REVIEWS (2018)

Add to Collection

Article Oncology

Randomised phase II trial to investigate catumaxomab (anti-EpCAM x anti-CD3) for treatment of peritoneal carcinomatosis in patients with gastric cancer

Maren Knoedler et al.

BRITISH JOURNAL OF CANCER (2018)

Add to Collection

Article Oncology

Phase II Study of the Dual EGFR/HER3 Inhibitor Duligotuzumab (MEHD7945A) versus Cetuximab in Combination with FOLFIRI in Second-Line RAS Wild-Type Metastatic Colorectal Cancer

Andrew G. Hill et al.

CLINICAL CANCER RESEARCH (2018)

Add to Collection

Article Pharmacology & Pharmacy

Emicizumab-kxwh: First Global Approval

Lesley J. Scott et al.

DRUGS (2018)

Add to Collection

Review Oncology

Recent advances of bispecific antibodies in solid tumors

Shengnan Yu et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)

Add to Collection

Article Medicine, General & Internal

Emicizumab Prophylaxis in Hemophilia A with Inhibitors

Johannes Oldenburg et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Review Oncology

Effectiveness and safety of PD-1/PD-L1 inhibitors in the treatment of solid tumors: a systematic review and meta-analysis

Xiaohui Wang et al.

ONCOTARGET (2017)

Add to Collection

Review Medicine, General & Internal

Cancer immunotherapy: the beginning of the end of cancer?

Sofia Farkona et al.

BMC MEDICINE (2016)

Add to Collection

Article Oncology

Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study)

Jerome Fayette et al.

FRONTIERS IN ONCOLOGY (2016)

Add to Collection

Article Oncology

FDA Approval: Blinatumomab

Donna Przepiorka et al.

CLINICAL CANCER RESEARCH (2015)

Add to Collection

Review Oncology

Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia

Jingjing Wu et al.

JOURNAL OF HEMATOLOGY & ONCOLOGY (2015)

Add to Collection

Article Oncology

The Role of Relative Lymphocyte Count as a Biomarker for the Effect of Catumaxomab on Survival in Malignant Ascites Patients: Results from a Phase II/III Study

Markus M. Heiss et al.

CLINICAL CANCER RESEARCH (2014)

Add to Collection

Article Oncology

Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone

P. Wimberger et al.

ANNALS OF ONCOLOGY (2012)

Add to Collection

Article Health Care Sciences & Services

GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables

Gordon Guyatt et al.

JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)

Add to Collection

Article Medicine, General & Internal

Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials

Jonathan A. C. Sterne et al.

BMJ-BRITISH MEDICAL JOURNAL (2011)

Add to Collection

Review Oncology

Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy

Diane Seimetz et al.

CANCER TREATMENT REVIEWS (2010)

Add to Collection

Article Oncology

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial

Markus M. Heiss et al.

INTERNATIONAL JOURNAL OF CANCER (2010)

Add to Collection

© Peeref 2019-2024. All rights reserved.